- The U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to DiaCarta's monkeypox virus detection test QuantiVirus MPXV.
- The PCR test is for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs and designed for use by authorized laboratories on qPCR instruments from Roche and Thermo Fisher, among others.
- DiaCarta said the test targets two different regions of the MPXV genome, which can help detect the virus even if a mutation occurs in one of the target regions.
- In October, 2022 it was reported that DiaCarta was going public on the NYSE via a merger with Hong Kong-based SPAC HH&L ( NYSE: HHLA ).
- HHLA +0.39% to $10.18 premarket Jan. 12
For further details see:
DiaCarta gets FDA emergency use nod for monkeypox test